Share：
Share this content in WeChat
X
[Chinese] [PDF] 51 1
• Reviews •
Application progress of multi-parametric magnetic resonance imaging radiomics in the diagnosis and treatment of lung cancer
LIU Zixuan  LIU Yulin 

Cite this article as LIU Z X, LIU Y L. Application progress of multi-parametric magnetic resonance imaging radiomics in the diagnosis and treatment of lung cancer[J]. Chin J Magn Reson Imaging, 2026, 17(8): 198-205. DOI:10.12015/issn.1674-8034.2026.08.023.


[Abstract] Lung cancer is the most prevalent malignancy worldwide. Magnetic resonance imaging (MRI) is non-ionizing, offers excellent soft-tissue resolution, and has versatile sequences. It plays a significant role in the precise evaluation of local tumor invasion, differentiating post-treatment changes and following up on high-risk populations. Additionally, it complements conventional CT and PET/CT effectively. As an emerging analytical technique that has developed rapidly in the field of medical imaging in recent years, radiomics has been shown in numerous studies to enable non-invasive precise diagnosis, individualized treatment decision-making and therapeutic response monitoring of lung cancer via radiomic models constructed by combining high-throughput quantitative imaging features with clinical data. As an emerging interdisciplinary method, mpMRI-based radiomics shows great potential in lung cancer diagnosis and treatment, but faces challenges including insufficient standardization of multi-center data, low feature reproducibility and inadequate model generalization ability. This review summarizes the applications of mpMRI radiomics in the precise diagnosis, classification, and staging of lung cancer, as well as the evaluation of treatment response and prognosis assessment, discusses current limitations and challenges, and aims to provide a reference for clinical decision-making in lung cancer, and to offer new perspectives for future research directions in this field.
[Keywords] lung cancer；magnetic resonance imaging；radiomics；machine learning；diagnosis and treatment applications

LIU Zixuan   LIU Yulin*  

Department of Radiology, Hubei Cancer Hospital Affiliated toTongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China

Corresponding author: LIU Y L, E-mail: liuyl26@163.com

Conflicts of interest   None.

Received  2026-04-05
Accepted  2026-08-03
DOI: 10.12015/issn.1674-8034.2026.08.023
Cite this article as LIU Z X, LIU Y L. Application progress of multi-parametric magnetic resonance imaging radiomics in the diagnosis and treatment of lung cancer[J]. Chin J Magn Reson Imaging, 2026, 17(8): 198-205. DOI:10.12015/issn.1674-8034.2026.08.023.

[1]
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]
GENET S A A M, VISSER E, YOUSSEF-EL SOUD M, et al. Strengths and challenges in current lung cancer care: Timeliness and diagnostic procedures in six Dutch hospitals[J/OL]. Lung Cancer, 2024, 189: 107477 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/38271919/. DOI: 10.1016/j.lungcan.2024.107477.
[3]
WU F, YIN Z R, ZHENG H R, et al. Opportunities and challenges in accurate early diagnosis and treatment of lung cancer/pulmonary nodules[J]. Natl Med J China, 2024, 104(18): 1547-1554. DOI: 10.3760/cma.j.cn112137-20240306-00508.
[4]
RUSHIN A, CHANG M C, GIACALONE A, et al. Magnetic resonance applications to metabolism[M]//Metabolomics: Methods and Protocols. New York, NY: Springer, 2025: 31-67.
[5]
NG A B C D, ASIF A, AGARWAL R, et al. Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial[J/OL]. Jama, 2025, 334(13): 1170 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/40928788/. DOI: 10.1001/jama.2025.13722.
[6]
ZHENG S Y, YANG Z H, DU G Z, et al. Discrimination between HER2-overexpressing, -low-expressing, and-zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics[J]. Eur Radiol, 2024, 34(9): 6132-6144. DOI: 10.1007/s00330-024-10641-7.
[7]
CAI Z P, XU Z Y, CHEN Y F, et al. Multiparametric MRI subregion radiomics for preoperative assessment of high-risk subregions in microsatellite instability of rectal cancer patients: a multicenter study[J]. Int J Surg, 2024, 110(7): 4310-4319. DOI: 10.1097/JS9.0000000000001335.
[8]
BIEDERER J, BERGMANN L L, ACKMAN J B, et al. MRI for lung cancer management: any closer to clinical application?[J]. J Magn Reson Imaging, 2026, 63(6): 1546-1561. DOI: 10.1002/jmri.70308.
[9]
PERNICIANO A, LODDO A, DI RUBERTO C, et al. Insights into radiomics: impact of feature selection and classification[J]. Multimed Tools Appl, 2025, 84(26): 31695-31721. DOI: 10.1007/s11042-024-20388-4.
[10]
HORNE A, ABRAVAN A, FORNACON-WOOD I, et al. Mastering CT-based radiomic research in lung cancer: a practical guide from study design to critical appraisal[J]. Br J Radiol, 2025, 98(1169): 653-668. DOI: 10.1093/bjr/tqaf051.
[11]
QI S N, WANG G L. Advances in multimodal imaging in lung cancer[J]. Chin J CT MRI, 2022, 20(12): 181-183. DOI: 10.3969/j.issn.1672-5131.2022.12.067.
[12]
SUROV A, BORGGREFE J, HÖHN A K, et al. Associations between ADC histogram analysis values and tumor-micro milieu in uterine cervical cancer[J/OL]. Cancer Imaging, 2024, 24(1): 170 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/39707580/. DOI: 10.1186/s40644-024-00814-4.
[13]
SUROV A, PECH M, OMARI J, et al. Diffusion-weighted imaging reflects tumor grading and microvascular invasion in hepatocellular carcinoma[J]. Liver Cancer, 2021, 10(1): 10-24. DOI: 10.1159/000511384.
[14]
HAN H Z, GUO W X, REN H, et al. Predictors of lung cancer subtypes and lymph node status in non-small-cell lung cancer: intravoxel incoherent motion parameters and extracellular volume fraction[J/OL]. Insights Imaging, 2024, 15(1): 168 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/38971908/. DOI: 10.1186/s13244-024-01758-w.
[15]
LÜ S Q, CAO G J, WANG W W, et al. Correlation between mono-and bi-exponential DWI models and expression of EGFR and ki-67 in lung adenocarcinoma[J]. J Clin Radiol, 2024, 43(1): 34-39.
[16]
BAO X, BIAN D L, YANG X, et al. Multiparametric MRI for evaluation of pathological response to the neoadjuvant chemo-immunotherapy in resectable non-small-cell lung cancer[J]. Eur Radiol, 2023, 33(12): 9182-9193. DOI: 10.1007/s00330-023-09813-8.
[17]
FU L, PAN X Y, DING H M, et al. The diagnostic value of vascular architecture in solid solitary pulmonary nodules quantified by dynamic contrast enhanced MRI[J]. J Thorac Dis, 2025, 17(1): 19-30. DOI: 10.21037/jtd-24-1467.
[18]
LAMBIN P, RIOS-VELAZQUEZ E, LEIJENAAR R, et al. Radiomics: extracting more information from medical images using advanced feature analysis[J]. Eur J Cancer, 2012, 48(4): 441-446. DOI: 10.1016/j.ejca.2011.11.036.
[19]
GILLIES R J, KINAHAN P E, HRICAK H. Radiomics: images are more than pictures, they are data[J]. Radiology, 2016, 278(2): 563-577. DOI: 10.1148/radiol.2015151169.
[20]
ZWANENBURG A, VALLIÈRES M, ABDALAH M A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping[J]. Radiology, 2020, 295(2): 328-338. DOI: 10.1148/radiol.2020191145.
[21]
AERTS H J, VELAZQUEZ E R, LEIJENAAR R T, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach[J/OL]. Nat Commun, 2014, 5: 4006 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/24892406/. DOI: 10.1038/ncomms5006.
[22]
WHYBRA P, ZWANENBURG A, ANDREARCZYK V, et al. The image biomarker standardization initiative: standardized convolutional filters for reproducible radiomics and enhanced clinical insights[J/OL]. Radiology, 2024, 310(2): e231319 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/38319168/. DOI: 10.1148/radiol.231319.
[23]
CABALLERO-VAZQUEZ A, GARCIA-CEREZO M, FERNANDEZ-CASTRO L R, et al. Liquid biopsy biomarkers for accurate detection of malignant pulmonary nodules: a meta-analytic approach[J/OL]. Discov Oncol, 2026, 17(1): 178 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/41612093/. DOI: 10.1007/s12672-025-03646-1.
[24]
HERNANDEZ A M, CHEN A F, SEN F, et al. A multireader, multicase study comparing ultra-high-resolution and conventional-resolution computed tomography for lung nodule characterization[J/OL]. J Clin Imaging Sci, 2025, 15: 25 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/40837596/. DOI: 10.25259/JCIS_17_2025.
[25]
TIETZ E, MÜLLER-FRANZES G, ZIMMERMANN M, et al. Evaluation of pulmonary nodules by radiologists vs. radiomics in stand-alone and complementary CT and MRI[J/OL]. Diagnostics, 2024, 14(5): 483 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/38472955/. DOI: 10.3390/diagnostics14050483.
[26]
HE Y S, DUAN S F, WANG W L, et al. Integrative radiomics clustering analysis to decipher breast cancer heterogeneity and prognostic indicators through multiparametric MRI[J/OL]. npj Breast Cancer, 2024, 10: 72 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/39112498/. DOI: 10.1038/s41523-024-00678-8.
[27]
KOO C W, KLINE T L, YOON J H, et al. Magnetic resonance radiomic feature performance in pulmonary nodule classification and impact of segmentation variability on radiomics[J/OL]. Br J Radiol, 2022, 95(1140): 20220230 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/36367095/. DOI: 10.1259/bjr.20220230.
[28]
XIE K X, CUI C, LI X Q, et al. MRI-based clinical-imaging-radiomics nomogram model for discriminating between benign and malignant solid pulmonary nodules or masses[J]. Acad Radiol, 2024, 31(10): 4231-4241. DOI: 10.1016/j.acra.2024.03.042.
[29]
ZHOU J X, WEN Y, DING R L, et al. Radiomics signature based on robust features derived from diffusion data for differentiation between benign and malignant solitary pulmonary lesions[J/OL]. Cancer Imaging, 2024, 24(1): 14 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/38246984/. DOI: 10.1186/s40644-024-00660-4.
[30]
WANG M M, JIANG J Q, XU G F, et al. Elaboration of multimodal MRI-based radiomics for predicting the histological subtypes of non-small-cell lung cancer[J]. Chin J Med Imaging, 2023, 31(10): 1064-1070. DOI: 10.3969/j.issn.1005-5185.2023.10.012.
[31]
TANG X, BAI G Y, WANG H, et al. Elaboration of multiparametric MRI-based radiomics signature for the preoperative quantitative identification of the histological grade in patients with non-small-cell lung cancer[J]. J Magn Reson Imaging, 2022, 56(2): 579-589. DOI: 10.1002/jmri.28051.
[32]
SUN L L, LUAN S H, YU L H, et al. Radiomic signatures of brain metastases on MRI: utility in predicting pathological subtypes of lung cancer[J]. Transl Cancer Res, 2024, 13(12): 6825-6836. DOI: 10.21037/tcr-24-1147.
[33]
SUI L Y, QUAN S, XING L H, et al. Identification of the pathological subtypes of lung cancer brain metastases with multiparametric MRI radiomics: a feasibility study[J/OL]. Sci Rep, 2025, 15: 26762 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/40702126/. DOI: 10.1038/s41598-025-11886-y.
[34]
GUGLIELMO P, MARTURANO F, BETTINELLI A, et al. Additional value of PET and CT image-based features in the detection of occult lymph node metastases in lung cancer: a systematic review of the literature[J/OL]. Diagnostics (Basel), 2023, 13(13): 2153 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/37443547/. DOI: 10.3390/diagnostics13132153.
[35]
WEI W, CHEN Q Q, MENG N, et al. Prediction of lymph node metastasis in non-small cell lung cancer and its correlation with Ki-67 expression: a comparative study between intravoxel incoherent motion imaging and 18F-FDG PET[J/OL]. BMC Med Imaging, 2026, 26(1): 64 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/41484705/. DOI: 10.1186/s12880-025-02131-z.
[36]
MENG N, LIU X, ZHOU Y H, et al. Multiparametric 18F-FDG PET/MRI based on restrictive spectrum imaging and amide proton transfer-weighted imaging facilitates the assessment of lymph node metastases in non-small cell lung cancer[J]. La Radiol Med, 2025, 130(7): 1003-1012. DOI: 10.1007/s11547-025-01992-2.
[37]
LI X C, CHANG N, ZHANG S, et al. Development and validation of an MRI-based clinical-radiomics nomogram for predicting lymph node metastasis in non-small cell lung cancer[J/OL]. BMC Med Imaging, 2026, 26(1): 268 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/41987095/. DOI: 10.1186/s12880-026-02357-5.
[38]
TANG X, BAI G Y, WANG H, et al. Predictive value for EGFR gene phenotype of lung adenocarcinoma based on multi -sequences MRI radiomics[J]. Radiologic Practice, 2021, 36(8): 1010-1015. DOI: 10.13609/j.cnki.1000-0313.2021.08.012.
[39]
WANG Y Z, WAN Q, XIA X Y, et al. Value of radiomics model based on multi-parametric magnetic resonance imaging in predicting epidermal growth factor receptor mutation status in patients with lung adenocarcinoma[J]. J Thorac Dis, 2021, 13(6): 3497-3508. DOI: 10.21037/jtd-20-3358.
[40]
WU P, GU X Y, LI D Y, et al. Clinical benefit of PD-1/PD-L1 inhibitors as standard first-line treatment in low PD-L1-expressing advanced solid tumors: a systematic review and meta-analysis[J/OL]. MedComm, 2026, 7(2): e70624 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/41675360/. DOI: 10.1002/mco2.70624.
[41]
FAWZUL AMEER S, ABDUL LATIF M SHARIF E, IBRAHIM W N. Hypoxia and HIF signalling in tumour microenvironment: linking immune evasion, metabolic rewiring and epigenetic regulation[J/OL]. Expert Rev Mol Med, 2026, 28: e14 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/41891153/. DOI: 10.1017/erm.2026.10044.
[42]
ROBUSTELLI TEST A, BORTOLOTTO C, THULASI SEETHA S, et al. Multisequence MRI-driven assessment of PD-L1 expression in non-small cell lung cancer: a pilot study[J/OL]. Biomed Phys Eng Express, 2025, 12(1) [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/41378488/. DOI: 10.1088/2057-1976/ae2621.
[43]
HAN Q J, LI S L, XIANG Z M. The value of T1 mapping and intravoxel incoherent motion parameters in predicting PD-L1 expression and dynamically monitoring immunotherapy in advanced lung cancer[J/OL]. Front Oncol, 2026, 16: 1687192 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/41768249/. DOI: 10.3389/fonc.2026.1687192.
[44]
BORTOLOTTO C, MESSANA G, TITO A L, et al. The role of native T1 and T2 mapping times in identifying PD-L1 expression and the histological subtype of NSCLCs[J/OL]. Cancers, 2023, 15(12): 3252 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/37370861/. DOI: 10.3390/cancers15123252.
[45]
LIU S Q, LV Y, DUAN L W, et al. Development and validation of multi-sequence magnetic resonance imaging radiomics models for predicting tumor response to radiotherapy in locally advanced non-small cell lung cancer[J]. J Thorac Dis, 2025, 17(3): 1684-1697. DOI: 10.21037/jtd-2025-142.
[46]
YANG C, ZHU F D, YANG J, et al. DCE-MRI quantitative analysis and MRI-based radiomics for predicting the early efficacy of microwave ablation in lung cancers[J/OL]. Cancer Imaging, 2025, 25(1): 26 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/40065426/. DOI: 10.1186/s40644-025-00851-7.
[47]
JIANG Z K, WANG B, HAN X, et al. Multimodality MRI-based radiomics approach to predict the posttreatment response of lung cancer brain metastases to gamma knife radiosurgery[J]. Eur Radiol, 2022, 32(4): 2266-2276. DOI: 10.1007/s00330-021-08368-w.
[48]
HEIDT C M, BOHN J R, STOLLMAYER R, et al. Delta-radiomics features of ADC maps as early predictors of treatment response in lung cancer[J/OL]. Insights Imaging, 2024, 15(1): 218 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/39186132/. DOI: 10.1186/s13244-024-01787-5.
[49]
KIM H, KIM J, HWANG S, et al. Enhancing identification of high-risk cN0 lung adenocarcinoma patients using MRI-based radiomic features[J]. Cancer Res Treat, 2025, 57(1): 57-69. DOI: 10.4143/crt.2024.251.
[50]
QI H R, HOU Y C, ZHENG Z H, et al. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases[J/OL]. BMC Cancer, 2024, 24(1): 362 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/38515096/. DOI: 10.1186/s12885-024-12121-z.
[51]
PONCE-BOBADILLA A V, SCHMITT V, MAIER C S, et al. Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development[J/OL]. Clin Transl Sci, 2024, 17(11): e70056 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/39463176/. DOI: 10.1111/cts.70056.
[52]
RAMASAMY G, SINGH T, YUAN X H, et al. MM-3DAttNet: multi-modal 3D attention network for MGMT methylation prediction[J/OL]. IEEE Open J Comput Soc, 2026, 7: 343-353 [2026-04-03]. https://ieeexplore.ieee.org/document/11352853. DOI: 10.1109/OJCS.2026.3654173.
[53]
CAPTIER N, LEROUSSEAU M, ORLHAC F, et al. Integration of clinical, pathological, radiological, and transcriptomic data improves prediction for first-line immunotherapy outcome in metastatic non-small cell lung cancer[J/OL]. Nat Commun, 2025, 16(1): 614 [2026-04-03]. https://pubmed.ncbi.nlm.nih.gov/39800784/. DOI: 10.1038/s41467-025-55847-5.

PREV Advances in the application of MRI for evaluating therapeutic efficacy of major treatment modalities in lung cancer
NEXT Research progress of gadoxetic acid disodium-enhanced MRI in predicting microvascular invasion of hepatocellular carcinoma
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn